Arch Biopartners Joins the Life Sciences Canadian Technology Accelerator in San Francisco
TORONTO, ONTARIO--(Marketwired - Aug. 14, 2013) - Arch Biopartners Inc (Arch) or (the Company)(CNSX:ACH) (OTCBB:FOIFF) announced today it has been accepted by the Consulate General of Canada, San Francisco/Silicon Valley to join the Life Sciences Canadian Technology Accelerator (CTA) at QB3 at the University of California San Francisco.
"This is an excellent opportunity for Arch to develop a presence in the U.S. market and advance its commercialization goals. The Arch team looks forward to becoming part of the California life science ecosystem with the help of the CTA program and the networking opportunities it provides," said Richard Muruve, CEO of Arch Biopartners.
About CTA@Mission Bay
The Trade Commissioner Service of Canada (TCS) and the Consulate General of Canada in San Francisco / Silicon Valley developed the CTA Program to provide Canadian companies with access to the unique resources of the Silicon Valley area.
The Consulate General has partnered with University of California, Quantitative Institute for Biosciences San Francisco (UCSF-QB3), to provide work spaces where qualified and selected TCS company clients can benefit for a limited period of time from the UCSF-QB3 ecosystem as well as dedicated TCS support.
In 2000, the University of California formed the California Institute for Quantitative Biosciences known as "QB3". QB3 is a cooperative effort among private industry and faculty at UCSF, UC Berkeley and UC Santa Cruz. One of four technology institutes created in 2000, QB3 has a joint mission of supporting science, driving the California economy and transforming scientific research into public good. For more information visit: www.qb3.org
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company's lead technology is in the area of targeting brain tumor initiating cells for the purpose of developing new imaging, diagnostic and therapeutic treatments for malignant glioma. The Company's website address is: www.archbiopartners.com .
For more information on the Company, please consult the other public documents filed on SEDAR at www.sedar.com.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.